⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14722547 | 0.84 | — | — | |
| SCHEMBL174227 | 0.78 | — | — | |
| SCHEMBL1346490 | 0.76 | HCAR2 (0.44) | — | |
| SCHEMBL2652640 | 0.75 | — | — | |
| SCHEMBL4264903 | 0.75 | — | — | |
| SCHEMBL1706467 | 0.75 | — | — | |
| SCHEMBL14723507 | 0.75 | — | — | |
| Hydrazine SCHEMBL6633032 | 0.75 | HCAR2 (0.46) | — | |
| SCHEMBL19732648 | 0.75 | — | — | |
| SCHEMBL3626143 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| CN-116003441-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-115925705-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-12-31 | — | — | CN | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-111601804-B | Nitrogen-containing heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-116003441-A | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115925705-A | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| CN-115667228-A | Salt and crystal form of heteroaromatic derivative and preparation method of salt and crystal form | 上海翰森生物医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| WO-2010144359-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| CN-101501030-A | Pyrimidine derivatives useful in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| CN-101437811-A | Quinoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |